Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

ImmunoPrecise Antibodies Ltd. (V:IPA)

Business Focus: Biopharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
 
Company Contact
Address: 3204-4464 Markham St
VICTORIA BC V8Z 7X8
Tel: N/A
Website: https://www.ipatherapeutics.com
IR: See website
Key People
Mitch Levine
Chairman of the Board
Jennifer Lynne Bath
President, Chief Executive Officer, Director
Kristin Taylor
Interim Chief Financial Officer
Ilse Roodink
Chief Scientific Officer
Kari Graber
Vice President - Commercial Services
 
Business Overview
ImmunoPrecise Antibodies Ltd. is a Canada-based biotherapeutic research and technology company. It leverages systems biology, multiomics modelling and artificial intelligence systems to support its technologies in bioplatform-based antibody discovery. Its services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners to discover and develop novel biologics. It utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases. It offers services, such as immunogen design and manufacturing, B cell sorting incorporating its function-first B cell screening and sequencing, and the production and screening of custom, immune, and naive phage display libraries. It also operates LSA instrument platform, which is a provider of high-throughput large and small molecule screening and characterization solutions.
Financial Overview
For the nine months ended 31 January 2024, Immunoprecise Antibodies Ltd revenues increased 20% to C$18.1M. Net loss decreased 57% to C$9.1M. Revenues reflect Project revenue segment increase from C$4.8M to C$11.3M, Product sales revenue segment increase from C$363K to C$972K, Antibody production segment increase of 10% to C$5.7M, Europe segment increase from C$1.9M to C$8M, United States of America segment increase from C$3M to C$9M.
Employees: 102 as of Apr 30, 2023
Reporting Currency: Canadian Dollars
Enterprise value: $40.57M as of Jan 31, 2024
Annual revenue (TTM): $17.45M as of Jan 31, 2024
EBITDA (TTM): -$7.73M as of Jan 31, 2024
Net annual income (TTM): -$10.51M as of Jan 31, 2024
Free cash flow (TTM): -$3.37M as of Jan 31, 2024
Net Debt Last Fiscal Year: $6.03M as of Jan 31, 2024
Shares outstanding: 26,315,260 as of Jan 31, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization